Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90

Journal of Medicinal Chemistry

Volumn 51, Issue 3, 2008, Pages 373-375

  Gopalsamy, Ariamala ^a   Shi, Mengxiao ^a   Golas, Jennifer ^a   Vogan, Erik ^b   Jacob, Jaison ^b   Johnson, Mark ^b   Lee, Frederick ^a,c   Nilakantan, Ramaswamy ^a   Petersen, Roseann ^a   Svenson, Kristin ^b   Chopra, Rajiv ^b,d   Tam, May S ^b   Wen, Yingxia ^b   Ellingboe, John ^a   Arndt, Kim ^a   Boschelli, Frank ^a  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

^c KEAN UNIVERSITY   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZISOXAZOLE DERIVATIVE; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; ISOXAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; K562 CELLS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 39149136212     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701385c     Document Type: Article

References (22)

1. de Jonge, M. J.; Verweij, J. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? Eur. J. Cancer 2006, 42 (10), 1351-1356.
2. Drysdale, M. J.; Brough, P. A.; Massey, A.; Jensen, M. R.; Schoepfer, J. Targeting Hsp90 for the treatment of cancer. Curr. Opin. Drug Discovery Dev. 2006, 9 (4), 483-495.
3. Solit, D. B.; Rosen, N. Hsp90: a novel target for cancer therapy. Curr. Top. Med. Chem. 2006, 6 (11), 1205-1214.
4. Neckers, L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. Pharmacol. 2006, (172), 259-277.
5. Frydman, J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 2001, 70, 603-647.
6. Walter, S.; Buchner, J. Molecular chaperones - cellular machines for protein folding. Angew. Chem., Int. Ed. 2002, 41 (7), 1098-1113.
7. Bukau, B.; Weissman, J.; Horwich, A. Molecular chaperones and protein quality control. Cell 2006, 125 (3), 443-451.
8. Picard, D. Chaperoning steroid hormone action. Trends Endocrinol. Metab. 2006, 17 (6), 229-235.
9. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci. 2002, 59 (10), 1640-1648.
10. Prodromou, C.; Pearl, L. H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 2003, 3 (5), 301-323.
11. Pearl, L. H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271-294.
12. A comprehensive listing is provided at the D. Picard lab Web site: http://www.picard.ch/downloads/downloads.htm.
13. (a) Xiao, L; Lu, X; Ruden, D. M. Effectiveness of Hsp90 inhibitors as anti-cancer drugs. Mini-Rev. Med. Chem. 2006, 6, 1137-1143.
14. (b) Chiosis, G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6, 1183-1191.
15. (c) Hadden, M. K.; Lubbers, D. J.; Blagg, B. S. J. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr. Top. Med. Chem. 2006, 6, 1173-1182.
16. (d) McDonald, E; Jones, K; Brough, P. A.; Drysdale, M. J.; Workman, P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6, 1193-1203.
17. (e) Dymock, B. W.; Barril, X; Brough, P. A.; Cansfleld, J. E.; Massey, A.; McDonald, E; Hubbard, R. E.; Surgenor, A; Roughley, S. D.; Webb, P; Workman, P; Wright, L; Drysdale, M. J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 2005, 48, 4212-4215.
18. (f) Smith, N. F.; Hayes, A.; James, K.; Nutley, B. P.; McDonald, E.; Henley, A.; Dymock, B.; Drysdale, M. J.; Raynaud, F. I.; Workman, P. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol. Cancer Ther. 2006, 5, 1628-1637.
19. Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screening 2004, 9 (5), 375-381.
20. PDB code for 6: 3BM9. PDB code for 13: 3BMY.
21. Malamas, M. S.; Manas, E. S.; McDevitt, R. E.; Gunawan, I; Xu, Z. B.; Collini, M. D.; Miller, C. P.; Dinh, T; Henderson, R. A.; Keith, J. C., Jr.; Harris, H. A. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J. Med. Chem. 2004, 47, 5021-5040.
22. The values represent an average of at least three independent determinations unless otherwise mentioned.